Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. The KOGENATE Study Group.

MLA

Seremetis, S., et al. “Human Recombinant DNA-Derived Antihaemophilic Factor (Factor VIII) in the Treatment of Haemophilia A: Conclusions of a 5-Year Study of Home Therapy. The KOGENATE Study Group.” Haemophilia : The Official Journal of the World Federation of Hemophilia, vol. 5, no. 1, Jan. 1999, pp. 9–16. EBSCOhost, https://doi.org/10.1046/j.1365-2516.1999.00191.x.

APA

Seremetis, S., Lusher, J. M., Abildgaard, C. F., Kasper, C. K., Allred, R., & Hurst, D. (1999). Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. The KOGENATE Study Group. Haemophilia : The Official Journal of the World Federation of Hemophilia, 5(1), 9–16. https://doi.org/10.1046/j.1365-2516.1999.00191.x

Chicago

Seremetis, S, J M Lusher, C F Abildgaard, C K Kasper, R Allred, and D Hurst. 1999. “Human Recombinant DNA-Derived Antihaemophilic Factor (Factor VIII) in the Treatment of Haemophilia A: Conclusions of a 5-Year Study of Home Therapy. The KOGENATE Study Group.” Haemophilia : The Official Journal of the World Federation of Hemophilia 5 (1): 9–16. doi:10.1046/j.1365-2516.1999.00191.x.